DaVita (DVA)
(Delayed Data from NYSE)
$138.48 USD
-1.89 (-1.35%)
Updated Aug 1, 2025 03:59 PM ET
After-Market: $138.46 -0.02 (-0.01%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth D Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
DVA 138.48 -1.89(-1.35%)
Will DVA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for DVA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for DVA
DaVita HealthCare (DVA) Registers a Bigger Fall Than the Market: Important Facts to Note
Can Phosphate Binders Drive DaVita Stock Before Q2 Earnings?
DVA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Chemed (CHE) Q2 Earnings Miss Estimates
DaVita HealthCare (DVA) Reports Next Week: Wall Street Expects Earnings Growth
Universal Health to Report Q2 Earnings: What Do the Key Estimates Say?
Other News for DVA
DaVita Inc (DVA) Partners with Food is Medicine Coalition to Address Chronic Illness and Food ...
Insider Sell Alert: James Hearty Sells Shares of DaVita Inc (DVA)
DaVita Breaks Above 200-Day Moving Average - Bullish for DVA
Fresenius Medical Care: Is Trading Below Its Intrinsic Value (Buy)
DaVita Inc (DVA) Announces Second Quarter 2025 Investor Conference Call | DVA stock news